Sunil Healthcare Ltd Upgraded to Sell on Improved Valuation and Financial Trends

Valuation Upgrade Spurs Rating Change

The most significant factor behind the upgrade is the shift in Sunil Healthcare’s valuation grade from “attractive” to “very attractive.” The company currently trades at a price-to-earnings (PE) ratio of 22.77, which is reasonable compared to peers such as Bliss GVS Pharma (PE 20.56) and significantly lower than more expensive competitors like Shukra Pharma (PE 62.12) and NGL Fine Chem (PE 38.83). The enterprise value to EBITDA ratio stands at 8.83, indicating a relatively modest valuation against earnings before interest, tax, depreciation, and amortisation.

Further valuation metrics reinforce this positive view: the price-to-book value is below 1 at 0.96, and the enterprise value to capital employed is an exceptionally low 0.98. The PEG ratio, which adjusts PE for earnings growth, is a mere 0.08, signalling undervaluation relative to the company’s growth prospects. These valuation parameters collectively suggest that Sunil Healthcare is trading at a discount compared to its sector peers, justifying the upgrade in investment rating.

Financial Trend Shows Signs of Improvement

Sunil Healthcare’s recent financial performance has also contributed to the rating revision. The company reported positive results for four consecutive quarters, with the latest half-year profit after tax (PAT) rising to ₹1.59 crores. Return on capital employed (ROCE) for the half-year improved to 6.69%, up from a long-term average of 5.21%, indicating better utilisation of capital resources.

Additionally, the debt-equity ratio has decreased to 0.88 times, reflecting a more manageable debt load and improved ability to service liabilities. However, the company’s debt to EBITDA ratio remains elevated at 5.63 times, which is a cautionary factor for long-term financial health. Despite this, the recent trend towards lower leverage and improved profitability has been viewed favourably by analysts.

Quality Assessment Remains Weak

Despite the valuation and financial trend improvements, Sunil Healthcare’s quality parameters continue to weigh on its rating. The company’s long-term fundamental strength is considered weak, with a modest average ROCE of 5.21% over recent years. Net sales growth has been sluggish, expanding at an annualised rate of only 1.43% over the past five years, which is below industry standards and insufficient to drive robust earnings growth.

Return on equity (ROE) is also low at 2.55%, indicating limited profitability relative to shareholder equity. These factors highlight ongoing challenges in operational efficiency and growth potential, which temper enthusiasm despite the improved valuation.

Technical Indicators and Market Performance

From a technical perspective, Sunil Healthcare’s stock price has shown limited momentum. The share price closed at ₹63.50 on 19 Mar 2026, up 1.37% from the previous close of ₹62.64, with intraday highs reaching ₹65.00. However, the stock remains closer to its 52-week low of ₹58.61 than its high of ₹88.70, reflecting subdued investor sentiment.

Performance relative to the broader market has been disappointing. Over the past year, the stock has declined by 5.37%, underperforming the BSE500 index, which gained 5.49% in the same period. Even over shorter time frames, such as one month and one week, Sunil Healthcare’s returns have been negative (-3.36% and -6.09%, respectively), while the Sensex has shown resilience.

Longer-term returns tell a mixed story: the stock has delivered a strong 156.57% gain over five years, outperforming the Sensex’s 55.85% return. However, over ten years, the stock has declined by 45.63%, contrasting sharply with the Sensex’s 207.40% gain. This volatility and inconsistency in returns contribute to a cautious technical outlook.

Micro-Cap Status and Market Position

Sunil Healthcare is classified as a micro-cap company within the Pharmaceuticals & Biotechnology sector, with a modest market capitalisation. This status often entails higher volatility and liquidity risks, which investors should consider alongside the company’s fundamentals. The majority shareholding remains with promoters, indicating stable ownership but also potential concentration risk.

The company’s Mojo Score stands at 32.0, reflecting a Sell rating, upgraded from a previous Strong Sell. This score integrates multiple parameters including valuation, quality, financial trends, and technicals, providing a comprehensive view of the stock’s investment appeal.

Summary and Outlook

In summary, Sunil Healthcare Ltd’s upgrade from Strong Sell to Sell is primarily driven by a very attractive valuation profile and improving financial trends, including better profitability and reduced leverage. However, the company’s weak long-term growth, modest returns on capital, and underwhelming market performance continue to constrain its outlook.

Investors should weigh the potential value opportunity against the risks posed by the company’s fundamental weaknesses and micro-cap status. While the recent positive quarterly results and valuation discount offer some encouragement, cautious monitoring of debt levels and sales growth remains essential.

Overall, the revised rating reflects a more balanced view, recognising progress while acknowledging persistent challenges in Sunil Healthcare’s business and market positioning.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →